NanoBio Corp. today
announced that it will present compelling new data for NB-003, the company's
nanoemulsion based clinical stage product for the treatment of acne. The information
will be delivered orally and in poster format at the Academy of Dermatology
Summer Meeting, taking place July 29-August 2nd at the Hynes Convention Center,
Boston, Mass. Posters will be available for download during the meeting and
from the NanoBio web site.
The oral presentation schedule is as follows:
Poster Presentation # 106 - Thursday, July 30, 10:00 AM
- Susceptibility of Propionibacterium acnes in the Presence of Sebum to NB-003
Poster Presentation # 109 - Thursday, July 30, 10:30 AM
- Novel Follicular-Targeted Nanoemulsion for Acne
NB-003 uniquely penetrates the skin and enters epidermal tissues targeting
the oil producing glands connected to a hair follicle. This penetration results
in effective delivery of the nanoemulsion droplets to the site of infection.
These droplets disrupt the P. acnes and are cidal on contact. NB-003 and other
NanoBio dermatological products are derived from NanoBio's patented NanoStat™
technology platform. NanoBio is currently conducting a Phase I study with NB-003.
NanoBio® Corp. is a privately held biopharmaceutical company focused on
developing and commercializing dermatological products, anti-infective treatments
and intranasal vaccines derived from its patented NanoStat™ technology
platform. The company's lead dermatology and anti-infective product candidates
include treatments for herpes labialis (cold sores), onychomycosis (nail fungus),
tinea capitis, acne, molluscum contagiosum, and cystic fibrosis. The company's
headquarters and laboratory facilities are located in Ann Arbor, Michigan.